Enzalutamide

TargetMol
Product Code: TAR-T6002
Supplier: TargetMol
CodeSizePrice
TAR-T6002-5mg5mg£104.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-10mg10mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-25mg25mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-50mg50mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-100mg100mg£196.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-200mg200mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-500mg500mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-1g1g£425.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6002-2g2g£624.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Enzalutamide (MDV 3100) is a non-steroidal androgen receptor (AR) antagonist (IC50: 36 nM in LNCaP prostate cells).
CAS:
915087-33-1
Formula:
C21H16F4N4O2S
Molecular Weight:
464.44
Pathway:
Autophagy; Endocrinology/Hormones
Purity:
0.9967
SMILES:
CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F
Target:
Androgen Receptor; Autophagy

References

Shi F, Wu L, Cui D, et al.LncFALEC recruits ART5/PARP1 and promotes castration-resistant prostate cancer through enhancing PARP1-meditated self PARylation.Cellular Oncology.2023: 1-16. Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38(11):2076-82. Ghoochani A, Hsu E C, Aslan M, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer[J]. Cancer research. 2021 Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790. Sun R, Yan B, Li H, et al.Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis.Cancer Research.2023 Ekiciler A, Chen W L K, Bo Y, et al.Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating Profiles.Drug Metabolism and Disposition.2023, 51(3): 276-284. Ghoochani A, Hsu E C, Aslan M, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer research. 2021 Mar 15;81(6):1583-1594. doi: 10.1158/0008-5472.CAN-20-3477. Epub 2021 Jan 22. Zhao J, Sun Y, Ren L, et al.Antagonism of androgen receptor signaling by aloe-emodin.Food and Chemical Toxicology.2023: 114092. Ren L, Luo H, Zhao J, et al.An integrated in vitro/in silico approach to assess the anti-androgenic potency of isobavachin.Food and Chemical Toxicology.2023: 113764. Pan W, Zhang Z, Kimball H, et al. Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells. Clinical Cancer Research. 2021, 27(7): 2087-2099.